Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer

E. A. Perez, D. R. Gandara

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Although non-small cell lung cancer has long been considered poorly responsive to chemotherapy, there are now a number of chemotherapeutic agents with reproducible activity in this disease, including cisplatin and ifosfamide. Another agent, etoposide, has been rationally incorporated into combination regimens for this disease based on demonstrated preclinical synergy. We review recent studies combining these three agents in the treatment of metastatic non-small cell lung cancer as well as prospects for further development.

Original languageEnglish (US)
Pages (from-to)2-5
Number of pages4
JournalSeminars in Oncology
Volume21
Issue number3 SUPPL. 4
StatePublished - 1994
Externally publishedYes

Fingerprint

Ifosfamide
Etoposide
Non-Small Cell Lung Carcinoma
Cisplatin
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer. / Perez, E. A.; Gandara, D. R.

In: Seminars in Oncology, Vol. 21, No. 3 SUPPL. 4, 1994, p. 2-5.

Research output: Contribution to journalArticle

Perez, EA & Gandara, DR 1994, 'Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer', Seminars in Oncology, vol. 21, no. 3 SUPPL. 4, pp. 2-5.
Perez, E. A. ; Gandara, D. R. / Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer. In: Seminars in Oncology. 1994 ; Vol. 21, No. 3 SUPPL. 4. pp. 2-5.
@article{476c752cac5c43aca0fe35ecb146361e,
title = "Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer",
abstract = "Although non-small cell lung cancer has long been considered poorly responsive to chemotherapy, there are now a number of chemotherapeutic agents with reproducible activity in this disease, including cisplatin and ifosfamide. Another agent, etoposide, has been rationally incorporated into combination regimens for this disease based on demonstrated preclinical synergy. We review recent studies combining these three agents in the treatment of metastatic non-small cell lung cancer as well as prospects for further development.",
author = "Perez, {E. A.} and Gandara, {D. R.}",
year = "1994",
language = "English (US)",
volume = "21",
pages = "2--5",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 4",

}

TY - JOUR

T1 - Etoposide/ifosfamide/cisplatin regimens in metastatic non-small cell lung cancer

AU - Perez, E. A.

AU - Gandara, D. R.

PY - 1994

Y1 - 1994

N2 - Although non-small cell lung cancer has long been considered poorly responsive to chemotherapy, there are now a number of chemotherapeutic agents with reproducible activity in this disease, including cisplatin and ifosfamide. Another agent, etoposide, has been rationally incorporated into combination regimens for this disease based on demonstrated preclinical synergy. We review recent studies combining these three agents in the treatment of metastatic non-small cell lung cancer as well as prospects for further development.

AB - Although non-small cell lung cancer has long been considered poorly responsive to chemotherapy, there are now a number of chemotherapeutic agents with reproducible activity in this disease, including cisplatin and ifosfamide. Another agent, etoposide, has been rationally incorporated into combination regimens for this disease based on demonstrated preclinical synergy. We review recent studies combining these three agents in the treatment of metastatic non-small cell lung cancer as well as prospects for further development.

UR - http://www.scopus.com/inward/record.url?scp=0028352234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028352234&partnerID=8YFLogxK

M3 - Article

VL - 21

SP - 2

EP - 5

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 4

ER -